PathAI scores $11M to ramp up deep-learning tech, grow team

PathAI's software is not yet available for clinical use, but the Cambridge, MA-based startup has partnered with Philips and Bristol-Myers Squibb on diagnostics and drug discovery respectively.

PathAI, which teamed up with Philips on cancer diagnostics in March, has bagged $11 million in series A financing. The startup will use the funds to build out its team and develop its artificial intelligence-based technology.

General Catalyst Partners led the round, while Pillar Companies, Refactor Capital, 8VC, Danhua Capital, and KdT Ventures also participated, Xconomy reported.

PathAI is developing deep-learning algorithms for the detection and diagnosis of disease. It aims to help pathologists, who analyze tissue and fluid samples in the lab to diagnose disease, perform their job more accurately and efficiently.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We see a big opportunity to solve a really major and longstanding problem, which is accurately diagnosing diseases and using that information to more effectively guide treatments for patients,” said CEO Andy Beck, Xconomy reported.

RELATED: Philips snaps up Northern Irish digital pathology startup PathXL

Philips and PathAI joined forces to apply deep learning to “massive” pathology datasets to improve diagnostic and treatment decisions. Their first focus is breast cancer—they will create deep-learning tools to automatically spot lesions in breast cancer tissue.

The duo hopes to ease the growing burden on pathologists, who have historically analyzed tumor samples manually. And they’re not the only ones—digital pathology startup 3Scan reeled in $14 million last year to further develop its image processing and analysis software, which would digitize pathology for clinical diagnostics and drug discovery.

PathAI has also partnered with Bristol-Myers Squibb, which is using its tech to review pathology samples and analyze patient response to drugs in clinical trials, Xconomy said.

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.